Maculopathy is a broad term for any disease or damage affecting the macula, the small patch of retina responsible for your sharpest central vision. Because this area drives everything from reading to recognizing faces, even mild maculopathy can interfere with daily life in ways that peripheral vision loss does not. The causes range from aging and diabetes to high myopia, medication side effects, and inherited gene mutations, and the treatments vary just as widely depending on which type is involved.
What the Macula Does and Why It Is Vulnerable
The macula sits near the center of the retina and spans only a few millimeters, but it accounts for the lion’s share of your detailed, color-sensitive vision. At its very center is the fovea, packed almost exclusively with cone photoreceptors arranged so densely that each cone feeds its signal through a dedicated chain of nerve cells to the brain. That one-to-one wiring is what gives you the resolution to read fine print or thread a needle.
This exquisite architecture comes at a cost. The fovea’s high metabolic demand, thin supporting layers, and dependence on a nourishing blood supply underneath make it sensitive to disruption. When the pigment layer beneath the photoreceptors breaks down, or when abnormal blood vessels leak fluid into the space, or when toxic byproducts accumulate, the macula loses function faster than the surrounding retina would under identical stress. That vulnerability is the common thread running through every form of maculopathy.
Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is by far the most common maculopathy and a leading cause of vision loss in older adults worldwide. It is split into two broad categories, often called “dry” and “wet,” and they behave quite differently.
Dry AMD and Geographic Atrophy
Dry AMD begins with the buildup of yellowish deposits called drusen beneath the retina. Early on, drusen may cause no noticeable symptoms. As the disease moves from early to intermediate stages, increasing drusen formation starts to damage the outer retinal cells, particularly the photoreceptors and the retinal pigment epithelium (RPE) that supports them. The late stage of dry AMD is called geographic atrophy (GA), in which whole patches of the photoreceptor layer, RPE, and the tiny blood vessel layer beneath them (the choriocapillaris) simply die off, leaving permanent blind spots in central vision.
The underlying biology of GA involves a tangle of factors including overactive inflammatory pathways, oxidative stress, and hardening of the choroidal blood vessels. For a long time there were no approved treatments, making GA a frustrating diagnosis for patients and clinicians alike. That changed recently with the approval of pegcetacoplan, an intravitreal complement inhibitor that slows, though does not stop, the rate at which atrophy expands.
Wet AMD
Wet (also called exudative or neovascular) AMD occurs when abnormal blood vessels sprout from beneath the retina and push into spaces where they do not belong. These vessels are fragile and leak fluid and blood, which lifts and damages the overlying retina. Left unchecked, the leaking leads to scarring and permanent central vision loss. Wet AMD can develop suddenly even in someone who previously had only mild dry AMD, which is why monitoring matters.
The good news is that wet AMD responds well to treatment with anti-VEGF injections, discussed below. Research is also exploring complementary approaches; one study in animal models found that a mineralocorticoid receptor blocker (spironolactone) reduced inflammatory cell recruitment into the damaged area through a pathway distinct from the one targeted by anti-VEGF drugs, lowering levels of inflammatory signaling molecules without directly affecting VEGF levels.
Diabetic Maculopathy
Diabetic macular edema (DME) is the most common cause of vision loss among people with diabetes. Chronic damage to the tiny blood vessels of the retina allows fluid to seep into the macula, causing it to swell. That swelling blurs and distorts central vision. The process is driven in large part by elevated levels of VEGF inside the eye, making it biologically related to wet AMD even though the underlying disease is very different.
Anti-VEGF injections have become the preferred first-line therapy for DME after multiple large clinical trials showed substantially better visual outcomes compared with the older standard of laser photocoagulation. Laser treatment, guided by protocols from the Early Treatment of Diabetic Retinopathy Study, remains available and is still used in some settings, but the shift toward anti-VEGF drugs has been dramatic.
Myopic Maculopathy
People with high or pathological myopia (severe nearsightedness) face their own form of macular disease. As the eyeball elongates, the retina and its supporting structures stretch and thin. The earliest visible change is a tessellated fundus, a mottled appearance caused by the choroidal vessels showing through the thinned tissue. Over time, breaks in the membrane beneath the retina (called lacquer cracks) may appear. These cracks are generally harmless on their own, but they can progress to patches of chorioretinal atrophy or trigger abnormal blood vessel growth similar to wet AMD.
A long-term natural history study documented the typical progression: tessellated fundus advances to diffuse atrophy and lacquer cracks; those cracks widen and may give way to patchy atrophy; existing patches enlarge and merge. Anti-VEGF injections can treat the neovascular complications when they arise, but the atrophic changes are irreversible, which makes monitoring highly myopic eyes over time especially important.
Toxic Maculopathy From Medications
Certain drugs can damage the macula as a side effect, and the most widely discussed offender is hydroxychloroquine (HCQ), commonly prescribed for lupus and rheumatoid arthritis. HCQ can cause an irreversible maculopathy that, once established, has no treatment. That makes early detection the entire strategy.
Revised screening guidelines from the American Academy of Ophthalmology recommend keeping the daily HCQ dose at or below 5 mg per kilogram of real body weight. At that dose, the risk of toxicity stays under one percent over the first five years and under two percent over ten years, but it climbs to roughly 20 percent after 20 years of use. Other risk factors include kidney disease and concurrent use of tamoxifen. Screening typically involves automated visual field testing and optical coherence tomography (OCT), and it should start after five years of use in patients on acceptable doses with no additional risk factors. In patients of Asian descent, the pattern of damage often appears outside the central macula, so screening protocols need to look beyond the fovea.
Inherited Macular Dystrophies
Not all maculopathies develop later in life. Stargardt disease, the most common inherited macular dystrophy, typically presents in childhood or young adulthood with progressive central vision loss. It is caused by mutations in the ABCA4 gene, which encodes a protein that clears toxic byproducts from photoreceptor cells. When the protein does not work properly, those byproducts accumulate and poison the RPE.
Genetic studies of childhood-onset Stargardt disease have found at least one disease-causing ABCA4 variant in about 90 percent of patients, with roughly 80 percent carrying two or more variants. Children with two severely damaging variants tend to have earlier and more aggressive disease compared with adults who carry milder combinations. Late-onset forms also exist and can be mistaken for AMD if genetic testing is not performed. No approved treatment currently exists for Stargardt disease, though gene therapy trials are underway, as discussed later.
Maculopathy From Retinal Vein Occlusion
When a vein draining blood from the retina becomes blocked, the resulting backup of pressure causes fluid to leak into the macula, producing macular edema. Retinal vein occlusion (RVO) is a leading cause of vision loss and most commonly affects people with high blood pressure, diabetes, or glaucoma. Anti-VEGF injections are the primary treatment, and a systematic review of randomized trials confirmed their effectiveness and safety for macular edema caused by RVO.
Vitreomacular Interface Disorders
Sometimes the problem starts not within the retina itself but at the junction between the retina and the vitreous gel that fills the eye. As people age, the vitreous gradually separates from the retinal surface. If separation is incomplete, the vitreous can exert traction on the macula, distorting it or even pulling a hole through its full thickness (a macular hole). Research on macular holes has shown that the direction of that traction matters: vertical pulling tends to produce wider holes with slower visual recovery after surgery compared with horizontal traction.
Epiretinal membranes, thin sheets of scar-like tissue that form on the macula’s surface, are another interface disorder. They wrinkle the underlying retina and blur or distort vision. Both macular holes and clinically significant epiretinal membranes are treated surgically, as described below.
Recognizing the Symptoms
Because maculopathy targets central vision, the symptoms tend to cluster in predictable ways regardless of the specific cause:
- Blurred central vision: fine detail becomes harder to resolve, even with corrective lenses.
- Metamorphopsia: straight lines appear wavy or bent, a hallmark of fluid or traction distorting the retinal surface.
- Central scotoma: a dark or blank spot in the center of your visual field.
- Difficulty with color or contrast: colors may look washed out, and distinguishing objects from their backgrounds becomes harder.
Metamorphopsia is especially telling. In one study of patients with diabetic macular edema, about half showed measurable metamorphopsia when tested with specialized charts, a higher detection rate than the traditional Amsler grid test alone could achieve. The Amsler grid, a simple printed grid you stare at with one eye, remains a useful home screening tool, but it can miss subtler distortion.
How Maculopathy Is Diagnosed
Optical coherence tomography (OCT) has become the gold standard for assessing macular disease. It produces cross-sectional images of the retina in exquisite detail, revealing fluid pockets, drusen, atrophy, traction, and membrane formation that may not be visible on a standard eye exam. For wet AMD specifically, OCT has high sensitivity for detecting abnormal blood vessel activity, though its specificity is only moderate, meaning it can sometimes flag findings that turn out not to be active disease.
Fluorescein angiography (FA) remains important for confirming and classifying abnormal blood vessels. A dye injected into the arm travels to the retinal vessels and highlights leakage. A newer, non-invasive alternative is OCT angiography (OCTA), which maps blood flow without any dye injection. Studies comparing OCTA with traditional angiography for detecting abnormal blood vessel growth in AMD have reported sensitivity in the high 80s to low 90s percent range and specificity around 68 to 90 percent, depending on the study and the type of vessel growth being detected. OCTA is increasingly used as a first-line tool, with dye angiography reserved for cases where the picture is ambiguous.
Anti-VEGF Injections
Anti-VEGF drugs are the workhorse treatment across multiple forms of maculopathy. Injected directly into the eye (which sounds worse than it feels, thanks to numbing drops), they block the signaling protein that drives abnormal blood vessel growth and vascular leakage. The main agents in clinical use include ranibizumab, aflibercept, and bevacizumab, and newer options like faricimab and brolucizumab have also entered the market. These drugs have been proven effective as first-line therapy for both wet AMD and diabetic macular edema, and they are also used for macular edema from retinal vein occlusion and for the neovascular complications of myopic maculopathy.
The chief downside is the treatment burden. Most patients need injections every four to eight weeks, at least initially, and some require ongoing treatment for years. Clinicians use various strategies to extend the interval between injections once the disease is stable, but the need for frequent monitoring visits remains a significant practical hurdle.
Complement Inhibitors for Geographic Atrophy
For years, dry AMD with geographic atrophy had no pharmacological treatment at all. The complement system, part of the body’s immune defense that becomes overactive in GA, emerged as a promising target. Most complement-targeting drugs tested in clinical trials failed, but pegcetacoplan broke through and received FDA approval for GA secondary to AMD, becoming the first therapy for this condition. Another complement inhibitor, avacincaptad pegol, followed closely. Both slow the rate at which the atrophic area expands rather than restoring lost vision, so they work best when started before atrophy reaches the very center of the macula.
Photodynamic Therapy
Before anti-VEGF injections existed, photodynamic therapy (PDT) was the primary treatment for wet AMD. A light-sensitive drug is injected intravenously and selectively taken up by abnormal blood vessels; a low-energy laser then activates the drug, damaging those vessels while sparing the overlying retina. In the landmark clinical trial, the rate of moderate or severe vision loss after one year was 39 percent in the PDT group compared with 54 percent in the placebo group. After two years, the gap persisted, with 54 percent of treated patients versus 67 percent of untreated patients experiencing moderate or severe impairment. PDT significantly slowed vision loss but rarely improved it, which is why anti-VEGF drugs have largely supplanted it. PDT still has a niche role in certain subtypes of wet AMD and in combination with anti-VEGF for stubborn cases.
Surgery for Macular Conditions
Vitrectomy with membrane peeling is the main surgical approach for vitreomacular interface problems. The surgeon removes the vitreous gel and peels away either an epiretinal membrane or the internal limiting membrane (ILM) from the macular surface. For full-thickness macular holes, this procedure has a high anatomical closure rate, and most patients gain significant visual improvement afterward.
The procedure is not without trade-offs. Studies using OCT to measure retinal thickness after ILM peeling have found that the temporal retina tends to thin while the nasal retina thickens, a pattern that appears regardless of whether the original problem was a macular hole or an epiretinal membrane. In patients who also have glaucoma, vitrectomy with ILM peeling can cause small but measurable deterioration at the very center of the visual field, even as peripheral visual field points improve. Risk factors for that central worsening include older age, high blood pressure, longer eye length, and heavier glaucoma medication use.
Gene Therapy on the Horizon
For inherited maculopathies like Stargardt disease, gene therapy represents the most promising avenue. Because the ABCA4 gene is too large to fit inside a standard gene-delivery vehicle, researchers have developed a dual-vector approach: two separate viral vectors each carry half of the gene, and once inside the retinal cells, the two halves are spliced together to produce the full-length ABCA4 protein. SpliceBio recently dosed the first patient in the Phase 1/2 ASTRA trial of SB-007, a therapy using exactly this strategy. Outcomes are years away, but the trial marks a concrete step toward treating a disease that currently has no approved therapy.
Nutritional Supplements and Prevention
You may have seen advertisements for eye-health supplements containing lutein, zeaxanthin, and omega-3 fatty acids. The large AREDS2 trial tested these nutrients head-to-head against placebo in people already at risk for advanced AMD. In the primary analysis, neither lutein plus zeaxanthin nor omega-3 fatty acids (DHA and EPA) produced a statistically significant reduction in the progression to advanced AMD. That does not mean these nutrients are worthless for eye health in a general sense, but the trial did not find the dramatic protective effect that supplement marketing sometimes implies. The original AREDS formula (vitamins C and E, zinc, and copper) showed more convincing benefit in earlier research and remains the basis for the supplements most retina specialists actually recommend to at-risk patients.
Home Monitoring With AI-Assisted OCT
One of the biggest challenges in managing wet AMD is catching reactivation of the disease between clinic visits. A new approach puts a small OCT device in the patient’s home, with an artificial intelligence algorithm analyzing each scan for signs of fluid accumulation. In a prospective trial of 15 patients who scanned their own eyes about six times per week, the home OCT system allowed the interval between injections to nearly double, from an average of eight weeks to over 15 weeks, with no significant change in visual acuity. The AI system reliably detected treatment-requiring fluid, supporting its use as a bridge between routine clinic appointments.
Low Vision Rehabilitation
When maculopathy causes irreversible central vision loss, low vision rehabilitation helps people make the most of their remaining sight. Programs typically combine magnification devices, training in eccentric viewing (learning to use a part of the retina adjacent to the damaged macula), contrast enhancement, and adaptive strategies for reading and daily tasks. A case series of patients with vision loss from myopic macular degeneration found that rehabilitation improved reading speed by 40 to 60 words per minute, boosted contrast sensitivity, and enhanced face recognition in every participant. These gains do not reverse the underlying disease, but they can meaningfully restore independence and quality of life.
Visual Hallucinations and Charles Bonnet Syndrome
One of the least discussed consequences of severe maculopathy is Charles Bonnet syndrome (CBS), in which people with significant vision loss experience vivid visual hallucinations despite having no psychiatric illness. In a study of patients with end-stage AMD, about 27 percent reported CBS. Poor visual acuity was the strongest predictor, with those whose best binocular vision was worse than about 20/200 being roughly three and a half times more likely to experience these images. The hallucinations were typically straight ahead, colored, and contained moving elements; the most common images were of people, followed by geometric patterns. Most patients described the experience as neither pleasant nor unpleasant, but many find it unsettling simply because they do not understand what is happening. Awareness that CBS is a recognized, benign consequence of vision loss, not a sign of cognitive decline, can be enormously reassuring.